Intellectual Property Law and Copyright Laws

Recent UK case law demonstrates how experimental evidence can decisively influence patent disputes on infringement and validity, but only when parties navigate strict procedural requirements, proportionate disclosure obligations, and careful alignment with patent specifications. Courts increasingly scrutinize the design, statistical rigor, and relevance of experiments while maintaining pragmatic standards for admissibility versus persuasiveness.

The rapid expansion of AI tools for intellectual property work has created an overwhelming landscape for patent attorneys and IP professionals. After analyzing practitioners who have moved beyond evaluation to live implementation, six consistent dimensions have emerged that distinguish truly adoptable AI tools from those that get set aside.

This September edition examines pivotal developments in life sciences patent law across Europe, with the Unified Patent Court continuing to refine its jurisprudence on added matter, intermediary liability, and procedural standards. National courts in the UK, France, and the Netherlands deliver significant rulings on supplementary protection certificates, pro-drugs, and the boundaries of pharmacy exemptions that will shape patent strategy for pharmaceutical and medical device companies.

M&S and Sephora have launched an exciting brand collaboration that brings together two highly recognisable retail names. Beyond the consumer appeal, this partnership raises important questions about trade mark licensing, co-branding arrangements, and how both parties maintain control over their valuable brand assets throughout the collaboration.

As artificial intelligence transforms ingredient discovery across pharmaceuticals, food, and biotechnology, companies face a critical challenge: when multiple organizations contribute data, AI models, and expertise to create new molecules and insights, who controls the resulting intellectual property? The answer requires rethinking traditional IP frameworks to account for datasets, model improvements, and experimental knowledge that may prove more valuable than the initial products themselves.

For many medical technology companies, a patent is the natural starting point when considering intellectual property protection for a new product.

As artificial intelligence transforms ingredient discovery across pharmaceuticals, food, and biotechnology, companies face a critical challenge: when multiple organizations contribute data, AI models, and expertise to create new molecules and insights, who controls the resulting intellectual property? The answer requires rethinking traditional IP frameworks to account for datasets, model improvements, and experimental knowledge that may prove more valuable than the initial products themselves.

As computational biology and artificial intelligence reshape drug discovery, pharmaceutical companies face a critical challenge: how to protect not just the final therapeutic compound, but the entire ecosystem of datasets, models, and biological insights that enabled its creation. This article examines the evolving intellectual property landscape where 90% of clinical candidates still fail, yet the tools predicting their success are becoming as valuable as the medicines themselves.

The European Health Data Space (EHDS) regulation has entered into force, creating a harmonised framework for cross-border health data access across the EU. While Europe possesses exceptional health data resources—particularly in Nordic countries with comprehensive patient registries—it has historically lacked the commercial data market infrastructure seen in the United States. This analysis explores how life science companies and investors can position themselves to capitalise on emerging opport

The Intellectual Property Enterprise Court has ruled that combining descriptive words like "flower" and "box" does not automatically create a descriptive trade mark, finding FLOWERBX valid and infringed by a competitor's similar branding. The decision demonstrates how strong evidence of brand recognition and actual consumer confusion can be decisive in trade mark enforcement cases, particularly in the context of online retail where visual similarity carries significant weight.

M&S and Sephora have launched an exciting brand collaboration that brings together two highly recognisable retail names. Beyond the consumer appeal, this partnership raises important questions about trade mark licensing, co-branding arrangements, and how both parties maintain control over their valuable brand assets throughout the collaboration.

Trade marks require genuine commercial use to maintain protection, but what constitutes "genuine use" in practice? Recent high-profile disputes, including X's battle over the Twitter brand, reveal how corporate rebrands and strategic shifts can expose even world-famous marks to revocation challenges. Understanding the nuances of use requirements and maintaining proper evidence has become critical for brand owners navigating M&A activity, product discontinuations, or market expansions.